Dukechem Bio Supplies Prostate Cancer Diagnostic Radiopharmaceutical 'FACBC' Domestically

[Asia Economy Reporter Byun Seon-jin] Radiopharmaceutical specialist pharmaceutical company Dukem Bio announced on the 7th that it will begin full-scale supply of the prostate cancer diagnostic radiopharmaceutical ‘FACBC (18F Fluciclovine)’ to the domestic market starting in November.

FACBC, known as Fluciclovine or Axumin, is a drug approved in 35 countries worldwide, including the US FDA in 2016 and the European EMA in 2017. It is reported to have been used in approximately 196,000 patients with recurrent prostate cancer to date. According to the Health Insurance Review & Assessment Service, the number of prostate cancer patients in Korea last year was 109,921, an increase of about 45% compared to 75,987 in 2017.

FACBC is a positron emission tomography (PET) diagnostic radiopharmaceutical for prostate cancer patients suspected of recurrence or metastasis, enabling optimal diagnosis even in cases where conventional imaging methods have limitations in tracking cancer lesions. Dukem Bio expects that the precise imaging diagnosis with FACBC will contribute to improving the treatment and management outcomes of patients with recurrent prostate cancer.

This content was produced with the assistance of AI translation services.